Targeted Therapy vs Chemotherapy: — 12 Differences That Actually Matter

Neither is better in the abstract. For patients whose tumour carries the specific molecular driver a targeted drug blocks, targeted therapy can outperform chemotherapy significantly. For patients without that driver, targeted therapy does little while still carrying real side effects. The question your oncologist answers is which treatment the evidence supports for your specific tumour biology — and that answer may well be chemotherapy, a combination, or something else entirely.

The side effects are different, not uniformly fewer. Targeted therapy is unlikely to cause significant hair loss, severe nausea, or the bone marrow suppression that chemotherapy can produce. Instead it can cause skin rash, dry skin, gut symptoms, changes to blood pressure, or effects on the liver, depending on the specific drug. Some people find these easier to live with; others find them more persistent because targeted therapy is taken every day rather than in cycles with recovery gaps. Ask your team which effects are most likely with the drug being considered for you.

Yes, and for several cancer types the standard approach is to combine both. Whether this applies to you depends on your cancer type, stage, and biomarker results. A combination carries the potential side effects of both treatments, which means closer monitoring. It is not a decision based on doing more — it is guided by what NCCN, ASCO, and ESMO evidence shows works for your specific diagnosis.

Eligibility is determined by your tumour biology, not your cancer type alone. Your tumour tissue needs to carry the specific molecular target — a mutation, a protein expression level, or a chromosomal rearrangement — that the drug is built to act on. That is established through biomarker testing, usually on tissue from a biopsy you have already had. If no actionable target is found, targeted therapy is not indicated. Your stage, general fitness, and treatment history also factor into the final recommendation.

Cancer cells can develop new mutations that allow them to bypass the pathway the drug is blocking. This is called acquired resistance and is one of the known limitations of targeted therapy. It does not mean treatment has ended — it means the tumour's biology has changed. The next step is usually further molecular testing to identify what has changed, and whether a different drug or regimen can address the new driver. Research into overcoming resistance is one of the most active areas in oncology today.

Your oncologist will arrange it if it applies to your diagnosis. Biomarker testing before treatment decisions is now standard practice for many cancer types where targeted therapies exist, and NCCN and ASCO guidelines specify when it is recommended. Testing is done on tumour tissue — usually from a biopsy already taken. If you have been diagnosed and no one has mentioned biomarker testing, it is entirely reasonable to ask your oncologist directly whether it applies to your case.

It depends on the specific drug. Many targeted therapies are taken as tablets or capsules at home, once or twice daily. Others are given as intravenous infusions at a clinic, similar to chemotherapy. At CION, intravenous targeted therapies are administered as day care, so you do not need to stay overnight. Your oncologist will explain the schedule, how often you need to come in, and what monitoring is required for whichever drug is prescribed.

A range of targeted therapies are approved by CDSCO, India's drug regulator, and are available in India. Access and cost vary by drug — some are available as generics, which substantially reduces the price, while others remain available only as originator brands. Your oncologist can advise on what is available for your cancer type, whether you are eligible, and what financial assistance programmes may apply. Any cost figure should be confirmed with your treating centre at the time of treatment, as prices change.